

## Amendments to the Claims

### 1-14. (Cancelled)

- 15. (Currently amended)** A compound selected from the group consisting of:
- 7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- N*-Cyclopropyl-7-(4-fluorobenzyl)-4-hydroxy-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2-morpholin-4-ylethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 4-Hydroxy-*N*-[2-(methyloxy)ethyl]-2-oxo-7-(phenylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-*N*-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-[(5-Fluoro-2-pyridinyl)methyl]-4-hydroxy-*N*-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;
- 7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-1-(cyclopropylmethyl)-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-Benzyl-4-hydroxy-*N*-(2-methoxyethyl)-2-oxo-1-(1,3-thiazol-2-ylmethyl)-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-(4-Fluorobenzyl)-4-hydroxy-*N*-(2-methoxyethyl)-1-[4-(methylsulfonyl)benzyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-[2-(4-morpholinyl)ethyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-[2-(methyloxy)ethyl]-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-{2-[(2-hydroxyethyl)oxy]ethyl}-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-(Dimethylamino)-2-oxoethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-*N*-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-*N*-[3-(2-oxo-1-pyrrolidinyl)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-*N*-[2-(4-morpholinyl)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-*N*-[3-(4-morpholinyl)propyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

~~7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;~~

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-N-[3-(2-oxo-1-pyrrolidiny)propyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-(methyloxy)ethyl]-1-[2-(4-methyl-1-piperaziny)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-N-[2-(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[2-hydroxy-1-methylethyl]-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

(±)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-[(2-hydroxypropyl)-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

N-[2-(ethyloxy)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-(2-{methyl[2-(methyloxy)ethyl]amino}-2-oxoethyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

1-[2-(Dimethylamino)-2-oxoethyl]-7-(4-fluorobenzyl)-4-hydroxy-N-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;

and or a pharmaceutically acceptable salts salt thereof.

**16-18. (Cancelled)**

**19. (Currently amended)** A compound according claim-~~5~~ 15 wherein the pharmaceutically acceptable salt is a sodium salt.

**20. (Withdrawn-currently amended)** A method of treatment of a viral infection in a human comprising administering to said human an antiviral effective amount of a compound according to claim-~~5~~ 15.

**21. (Withdrawn-currently amended)** A method according to claim 20 wherein the viral infection is a ~~a~~an HIV infection.

**22-24. (Cancelled)**

**25. (Currently amended)** A pharmaceutical composition comprising an effective amount of a compound according to claim ~~5~~ 15 together with a pharmaceutically acceptable carrier.

**26. (Original)** A pharmaceutical composition according to claim 25 in the form of a tablet or capsule.

**27. (Original)** A pharmaceutical composition according to claim 25 in the form of a liquid or suspension.

**28. (Withdrawn-currently amended)** A method of treatment of a viral infection in a human comprising administering to said human a composition comprising a compound according to claim ~~5~~ 15 and another therapeutic agent.

**29. (Withdrawn)** The method according to claim 28 wherein the viral infection is an HIV infection.

**30-32. (Cancelled)**

**33. (Previously presented)** 7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.

**34. (Previously presented)** 7-[(4-Fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide sodium salt.

**35. (Withdrawn)** A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of 7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide or a pharmaceutically acceptable salt thereof.

**36. (Previously presented)** A pharmaceutical composition comprising an effective amount of 7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

**37. (Previously presented)** A pharmaceutical composition according to claim 36 in the form of a tablet or capsule.

**38. (Previously presented)** A pharmaceutical composition according to claim 36 in the form of a liquid or suspension.

**39. (Withdrawn)** A method of treatment of an HIV infection in a human comprising administering to said human a composition comprising 7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof, and another therapeutic agent.

**40. (Withdrawn)** A pharmaceutical composition according to claim 36 wherein said composition comprises at least one additional therapeutic agent.

**41. (New)** A compound selected from the group consisting of:  
sodium 1-ethyl-7-[(4-fluorophenyl)methyl]-3-({[(1*S*)-2-hydroxy-1-methylethyl]amino}carbonyl)-  
2-oxo-1,2-dihydro-1,5-naphthyridin-4-olate;  
1-(2-Amino-2-oxoethyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-[2-(methyloxy)ethyl]-2-oxo-  
1,2-dihydro-1,5-naphthyridine-3-carboxamide;  
1-(4-Fluorophenyl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-(2-hydroxyethyl)-2-oxo-1,2-  
dihydro-1,5-naphthyridine-3-carboxamide;  
7-(4-Fluorobenzyl)-4-hydroxy-*N*-[(2*S*)-2-hydroxypropyl]-2-oxo-1-[2-(2-oxopyrrolidin-1-  
yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;  
7-(4-Fluorobenzyl)-4-hydroxy-*N*-[(2*R*)-2-hydroxypropyl]-2-oxo-1-[2-(2-oxopyrrolidin-1-  
yl)ethyl]-1,2-dihydro-1,5-naphthyridine-3-carboxamide;  
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[2-(methylamino)-2-oxoethyl]-*N*-[2-(methyloxy)ethyl]-  
2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;  
7-[(4-Fluorophenyl)methyl]-4-hydroxy-1-[(1-methyl-1*H*-imidazol-2-yl)methyl]-*N*-[2-  
(methyloxy)ethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide;  
*N*-[(2*R*)-2,3-Dihydroxypropyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-  
dihydro-1,5-naphthyridine-3-carboxamide;  
1-Ethyl-7-[(4-fluorophenyl)methyl]-4-hydroxy-*N*-[(1*S*)-2-hydroxy-1-methylethyl]-2-oxo-1,2-  
dihydro-1,5-naphthyridine-3-carboxamide;  
or a pharmaceutically acceptable salt thereof.

**42. (New)** A compound according claim 41 wherein the pharmaceutically acceptable salt is a sodium salt.

**43. (New)** A method of treatment of a viral infection in a human comprising administering to said human an antiviral effective amount of a compound according to claim 41.

**44. (New)** A method according to claim 43 wherein the viral infection is an HIV infection.

**45. (New)** A pharmaceutical composition comprising an effective amount of a compound according to claim 41 together with a pharmaceutically acceptable carrier.

**46. (New)** A pharmaceutical composition according to claim 45 in the form of a tablet or capsule.

**47. (New)** A pharmaceutical composition according to claim 45 in the form of a liquid or suspension.

**48. (New)** A method of treatment of a viral infection in a human comprising administering to said human a composition comprising a compound according to claim 41 and another therapeutic agent.

**49. (New)** The method according to claim 48 wherein the viral infection is an HIV infection.